Kevin Joseph Fitzgerald sold $418k of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 1,291 shares at an average of $323.54, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +15RoleOfficer
- +16Trade size$418k at market
- 0Share of holdings soldSold 5.9% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m -5.5%, 6m -17.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-26-000059, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -29 | $319.03 | $9,252 | 21,831 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -28 | $320.01 | $8,960 | 21,803 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -59 | $320.81 | $19k | 21,744 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -79 | $321.82 | $25k | 21,665 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -96 | $323.01 | $31k | 21,569 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -210 | $323.84 | $68k | 21,359 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -75 | $324.88 | $24k | 21,284 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -57 | $325.67 | $19k | 21,227 | Mar 6, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -124 | $321.81 | $40k | 21,103 | Mar 6, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -233 | $323.25 | $75k | 20,870 | Mar 6, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -148 | $324.60 | $48k | 20,722 | Mar 6, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -153 | $326.24 | $50k | 20,569 | Mar 6, 2026 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.